Az empagliflozin javítja a hepatikus dysfunctiót, csökkenti a májsteatosist 2-es típusú cukorbetegekben

there are some which positively affect hepatic steatosis. Sodium glucose co-transporter-2 inhibitors also may improve hepatic steatosis on the basis of their mech-anism of action. The goal of our study was to evaluate the empagliflozin’s effect on hepatic steatosis. The study includ-ed 38 patients with type 2 diabetes, who were treated with daily 10–25 mg empagliflozin in addition to standard therapy. Laboratory and clinical parameters were tested before and during the follow-up of empagliflozin treatment. The average follow-up time was 32 weeks. For the assessment of the liver steatosis we used the hepatic steatosis index (HSI) and the ZJU score. The results were evaluated by Student's test. The effect of add-on empagliflozin therapy reduced the HbA 1c value from 8.39±1.24% to 7.33±0.71% (p<0.001) and the BMI from 33.16±4.85 kg/m 2 to 32.02±4.78 kg/m 2 (p<0.001). The value of triglyceride was reduced by 0.16 mmol/l, while the value of the HDL-cholesterol increased, but these changes were not significant. The HSI score decreased from 46.73±5.51 to 45.45±5.94 (p=0.001), and the ZJU index from 50.92±6.84 to 47.83±5.77 (p<0.001). The empagliflozin treatment causes significant improvement in glycemic control, weight loss and reduces the hepatic steatosis in type 2 diabetes.